Video interview with Dr Isabelle Schiffer on senolytic safety

Forever Healthy Foundation issues risk-benefit analysis on dasatinib + quercetin as a senolytic.

The Forever Healthy Foundation published its latest risk-benefit analysis, which explores the combined use of cancer drug dasatinib with quercetin, a polyphenol common in plants, as a senolytic therapy.

After screening more than 3300 scientific papers and analysing more than 150 clinical and pre-clinical studies, Forever Healthy concludes that the use of DQ as a senolytic therapy should be avoided – “until there are more published results showing benefits in humans, a clearer picture of the senolytic-use specific risk profile, and a consensus on treatment protocols.”

Learn more in this exclusive video interview with Dr Isabelle Schiffer, the scientific spokesperson for Forever Healthy:

Image courtesy of the Forever Healthy Foundation


Danny Sullivan
Contributing Editor Danny has worked in technology communications for more than 15 years, spanning Europe and North America. From bionics and lasers to software and pharmaceuticals – and everything in between – he’s covered it all. Danny has wide experience of technology publishing and technical writing and has specific interest in the transfer from idea to market.

Latest articles

Reproductive Longevity – taking the geroscience approach

Applying geroscience interventions to fertility pathways can promote reproductive Longevity. Dr Joon Yun is President and Managing Partner of Palo Alto Investors, LP, a hedge...

Targeting senescent cells to extend lifespan

Although our understanding of the mechanisms underlying aging is limited, recent findings from animal studies indicate that targeting cellular senescence in vivo may prevent...

At-home wellness biomarker test to deliver instant results

ZiO Health prepares to launch crowdfunding campaign for subscription-based urine test that measures multiple health biomarkers. Biomedical start-up ZiO Health is on a mission to...

Inflammaging biotech acquired by Roche for €380m

One of the largest deals in Irish biotech history sees Roche gain rights to full Inflazome portfolio. The Swiss company Roche has bought Dublin-based biotech...